New injection shows promise for reducing excessive drooling

NCT ID NCT01994109

Completed Symptom relief Sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC Source: ClinicalTrials.gov ↗

First seen Apr 24, 2026

Summary

This Phase 3 study tested whether injections of MYOBLOC (a botulinum toxin type B) into the salivary glands can safely reduce troublesome drooling in adults. 187 participants received either MYOBLOC or a placebo. The main goals were to measure changes in saliva flow and overall improvement at 4 weeks. Results showed that MYOBLOC effectively decreased saliva production and improved symptoms compared to placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Study site

Loma Linda, California, 92354, United States
Study site

Los Angeles, California, 90033, United States
Study site

National City, California, 91950, United States
Study site

Aurora, Colorado, 80045, United States
Study site

Washington D.C., District of Columbia, 20007, United States
Study site

Boca Raton, Florida, 33486, United States
Study site

Port Charlotte, Florida, 33980, United States
Study site

Carmel, Indiana, 46032, United States
Study site

Baltimore, Maryland, 21287, United States
Study site

Elkridge, Maryland, 21075, United States
Study site

Detroit, Michigan, 48334, United States
Study site

St Louis, Missouri, 63110, United States
Study site

Edison, New Jersey, 08818, United States
Study site

Albany, New York, 12208, United States
Study site

New York, New York, 10003, United States
Study site

Cincinnati, Ohio, 45219, United States
Study site

Tulsa, Oklahoma, 74136, United States
Study site

Port Royal, South Carolina, 29935, United States
Study site

Cordova, Tennessee, 38018, United States
Study site

Houston, Texas, 77030, United States
Study site

San Antonio, Texas, 78229, United States
Study site

Salt Lake City, Utah, 84132, United States
Study site

Kirkland, Washington, 98034, United States
Study site

Tacoma, Washington, 98409, United States
Study site

Irkutsk, Irkutsk Oblast, 664079, Russia
Study site

Vsevolozhsk, Leningradskaya Oblast', 188643, Russia
Study site

Saint Petersburg, Petrodvorets, 198510, Russia
Study site

Krasnoyarsk, 660037, Russia
Study site

Dnipropetrovsk, 49027, Ukraine
Study site

Ivano-Frankivsk, 76008, Ukraine
Study site

Kharkiv, 61068, Ukraine
Study site

Lviv, 79010, Ukraine
Study site

Rivne, 33010, Ukraine
Study site

Uzhhorod, 88018, Ukraine

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MYOBLOC (rimabotulinumtoxinB, botulinum toxin type B)

What this could lead to

If it works, this could provide a safe and effective treatment option for adults with troublesome drooling due to various medical conditions.

What could go wrong

This is a completed Phase 3 trial, so results are more reliable, but individual responses may vary and there are risks like dry mouth or injection site reactions.

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis Parkinson disease Sialorrhea stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SIALORRHEA